Trials and Noteworthy Treatments

News Stories

(Relevance) Question - click to see the response!
Displaying 1 to 26 of 57
Click HERE for Next 25 articles!

(Relevance) Page Title - click title to go to the page!

•   (0.7967)   Technique Could Speed New Medulloblastoma Drugs
  
  
•   (0.7967)   Stem Cells Found In Cerebellum; Possible Cell Of Origin For Childhood Brain Tumors
  
  
•   (0.7967)   Introgen`s Anti-Cancer Therapy in Combination With Established Cancer Treatments Awarded Patent (PR Newswire)
  ... trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......Introgen`s second product candidate, INGN 241 (Adenoviral-mda7) for the treatment of solid tumors, is in Phase I clinical development....
  - Sep 06 7:30 AM ET
  
  
•   (0.7967)   PCV and/or TMZ chemotherapy in 255 gliomas. Analysis of the clinical experience from a neuro-oncology data-base.
  
  
•   (0.7742)   Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma
  
  
•   (0.7742)   A CANCER DRUG’S BIG PRICE RISE IS CAUSE FOR CONCERN
  
  
•   (0.7742)   Molecularly Targeted Therapy for Pediatric Brain Tumors.
  
  
•   (0.7742)   Etoposide Nanocarriers Suppress Glioma Cell Growth by Intracellular Drug Delivery and Simultaneous P-Glycoprotein Inhibition
  
  
•   (0.7742)   Hearing Loss From Chemotherapy Underestimated Say Researchers At Oregon Health and Sciences University
  
  
•   (0.7742)   New approach to chemo: Continuous, lower doses
  
  
•   (0.7742)   Parents face choice in treating childhood cancer
  
  
•   (0.7742)   Abbott Labs Intends to Submit New Drug Application for Xinlay™ (Atrasentan) for men with metastatic, hormone–refractory prostate cancer [Editor`s Note: mentions brain tumors also]
  
  
•   (0.7742)   A phase II trial of pre-irradiation chemotherapy with BCNU, cisplatin and oral etoposide combined with radiation therapy in the treatment of glioblastoma (GBM) No significant improvement in survival rate with this pre-irradiation chemotherapy.
  
  
•   (0.7742)   More Children Surviving Cancer, UK Experts Say (Reuters)
  ... according to Saha.SIDE EFFECTSEarlier treatments sometimes caused secondary tumors or heart disease later in life, but with improvements in drug therapies many such dangerous......After leukemia, brain and spinal tumors and lymphomas are the most common cancers in children. ...
  - Dec 03 1:27 PM ET
  
  
•   (0.7742)   More Children Surviving Cancer, UK Experts Say (Reuters)
  ... according to Saha.SIDE EFFECTSEarlier treatments sometimes caused secondary tumors or heart disease later in life, but with improvements in drug therapies many of the dangerous......After leukemia, brain and spinal tumors and lymphomas are the most common cancers in children. ...
  - Dec 03 9:38 AM ET
  
  
•   (0.7742)   Introgen to Present at Annual BIO-Europe Conference (PR Newswire)
  ... trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......Introgen`s second product candidate, INGN 241 (Adenoviral-mda7) for the treatment of solid tumors, is in Phase I clinical development....
  - Nov 12 4:00 AM ET
  
  
•   (0.7742)   Introgen`s PTEN Gene Drug May Provide Colorectal Cancer Treatment (PR Newswire)
  Introgen Therapeutics, Inc. announced that INGN 251, its PTEN gene drug, inhibits human colorectal tumors in animals.
  - Nov 01 10:01 AM ET
  
  
•   (0.7742)   Introgen Therapeutics Announces Third Quarter 2001 Results (PR Newswire)
  ... trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......Introgen`s second product candidate, INGN 241 (Adenoviral-mda7) for the treatment of solid tumors, is in Phase I clinical development....
  - Oct 30 4:04 PM ET
  
  
•   (0.7742)   Introgen Announces Earnings Conference Call (Business Wire)
  ... trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......Introgen`s second product candidate, INGN 241 (Adenoviral-mda7) for the treatment of solid tumors, is in Phase I clinical development....
  - Oct 26 5:23 PM ET
  
  
•   (0.7742)   Introgen`s INGN 241 Gene Drug Demonstrates Tumor Growth Control (PR Newswire)
  ...First, how MDA-7 protein is regulated as tumors develop from benign moles to the full-blown skin cancer known as melanoma and secondly,......This study demonstrates that mda-7 is a key tumor suppressor gene whose function is lost as melanoma tumors grow more aggressively....... trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer....
  - Oct 25 7:04 AM ET
  
  
•   (0.7742)   Gene Associated With Cancer and Other Diseases Awarded Patent and Licensed By Introgen (PR Newswire)
  ... collaborated since 1998 in the identification and pre- clinical development of a number of tumor suppressor genes.......Adenoviral-PTEN significantly slows the growth of human tumors, grown in animal models....... trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer....
  - Oct 23 7:03 AM ET
  
  
•   (0.7742)   Introgen to Present at Techvest Healthcare Conference (PR Newswire)
  ... trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......Introgen`s second product candidate, INGN 241 (Adenoviral-mda7) for the treatment of solid tumors, is in Phase I clinical development....
  - Oct 22 7:33 AM ET
  
  
•   (0.7742)   Introgen Gene Therapy Featured in Abstract and Published in Circulation, Journal of the American Heart Association (PR Newswire)
  ... trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......Introgen`s second product candidate, INGN 241 (Adenoviral-mda7) for the treatment of solid tumors, is in Phase I clinical development....
  - Oct 18 7:00 AM ET
  
  
•   (0.7742)   New Family of Ten Cancer Related Genes Is Discovered By Researchers at The National Cancer Institute, The University of Texas` Southwestern Medical Center and M. D. Anderson Cancer Center (PR Newswire)
  ...Discovery of these tumor suppressor genes represents a joint collaborative effort by scientists at The University of...... have been incorporated into gene delivery systems and have blocked the growth of established tumors in animal models of lung cancer....... trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer....
  - Oct 11 6:00 AM ET
  
  
•   (0.7742)   Introgen to Present at UBS Warburg Annual Healthcare Conference (PR Newswire)
  ... trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......Introgen`s second product candidate, INGN 241 (Adenoviral-mda7) for the treatment of solid tumors, is in Phase I clinical development....
  - Oct 10 7:31 AM ET
  
  

Frequently Asked Questions

(Relevance) Question - click to see the response!
Displaying 1 to 2 of 2